. Author manuscript; available in PMC: 2020 Apr 24.

Published in final edited form as: Eur Respir J. 2019 Oct 24;54(4):1900761. doi: 10.1183/13993003.00761-2019

TABLE 2.

Effect of prenatal vitamin D supplementation versus placebo on the development of asthma/persistent wheeze from 0 to 3 years in the VDAART and COPSAC₂₀₁₀ trials stratified by genotype of the 17q21 functional SNP rs12936231

rs12936231 strata	VDAART^#			COPSAC₂₀₁₀^¶			Combined analyses
rs12936231 strata	Total/cases n	HR (95% CI)	p-value	Total/cases n	HR (95% CI)	p-value	HR⁺ (95% CI)	p-value
GG	134/23	0.51 (0.21–1.19)	0.119	137/19	0.48 (0.18–1.27)	0.140	0.49 (0.26–0.94)	0.032
GC	313/101	0.75 (0.50–1.11)	0.147	259/40	0.73 (0.39–1.37)	0.327	0.74 (0.53–1.04)	0.080
CC	171/44	1.07 (0.59–1.95)	0.821	121/33	1.08 (0.55–2.15)	0.822	1.08 (0.69–1.69)	0.751

Cases refer to the number of children with asthma/persistent wheeze at from age 0 to 3 years. VDAART: Vitamin D Antenatal Asthma Reduction Trial; COPSAC₂₀₁₀: Copenhagen Prospective Studies on Asthma in Childhood 2010; SNP: single nucleotide polymorphism.

^#:

n=618;

^¶:

n=517;

^{+ :}

fixed-effects meta-analysis HR combining VDAART and COPSAC_2010.